Jonathan Z. Ho - Concepedia

Author

Jonathan Z. Ho

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

JONATHAN Z HO, Jonathan Ho, Jonathan Z Ho, Jonathan Z. Ho, Jonathan Z. Ho

Publications

461

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, Berkeley Cairo University

About

Jonathan Z. Ho is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, organic chemistry, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	129
2	Natural Sciences	5	5	126
3	Biochemistry	3	3	78
4	Engineering	2	2	51
5	Biology	1	1	31

Jonathan Z. Ho

Publications

410

Citations

H-Index

Page 1

	Year	Citations
Enantiospecific Synthesis of Carbapentostatins Jonathan Z. Ho, Rafat M. Mohareb, Jin Hee Ahn, The Journal of Organic Chemistry	2002	45
Carbocationic Rearrangements of Silphinane Derivatives Robert M. Coates, Jonathan Z. Ho, Michael Klobus, The Journal of Organic Chemistry Derivative (Chemistry)EngineeringSilphin-7-yl IonBiochemistrySilphinane Family	1998	39
Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans Sanjeev Kumar, Eugene Y. Tan, Georgy Hartmann, Drug Metabolism and Disposition	2009	35
Novel, Potent Non-Covalent Thrombin Inhibitors Incorporating P3-Lactam Scaffolds Jonathan Z. Ho, Tony Gibson, J. Edward Semple Bioorganic & Medicinal Chemistry Letters ThrombosisMedicinal ChemistryMedicineDrug DiscoveryFibrinolysis	2002	32
Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys Eugene Y. Tan, Georgy Hartmann, Qing Chen, Drug Metabolism and Disposition	2009	31
Identification of distinctive molecular traits that are characteristic of the phylum “Deinococcus-Thermus” and distinguish its main constituent groups Jonathan Z. Ho, Mobolaji Adeolu, Bijendra Khadka, Systematic and Applied Microbiology BiologyMain Constituent GroupsMicrobial SystematicsPhylogeneticsMolecular Ecology	2016	31
Non-covalent thrombin inhibitors featuring p3-heterocycles with P1-monocyclic arginine surrogates John Reiner, Daniel V. Siev, Gian‐Luca Araldi, Bioorganic & Medicinal Chemistry Letters	2002	31
Bioactivation of 2,3-Diaminopyridine-Containing Bradykinin B<sub>1</sub> Receptor Antagonists: Irreversible Binding to Liver Microsomal Proteins and Formation of Glutathione Conjugates Cuyue Tang, Raju Subramanian, Yuhsin Kuo, Chemical Research in Toxicology	2005	29
Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates Jingrong Jean Cui, Gian‐Luca Araldi, John Reiner, Bioorganic & Medicinal Chemistry Letters ThrombosisMedicinal ChemistryMedicineNon-covalent Thrombin InhibitorsPharmacotherapy	2002	27
Use of Dibutyl[<sup>14</sup>C]formamide as a Formylating Reagent in the <i>Vilsmeier</i>–<i>Haack</i> Reaction and Synthesis of a <sup>14</sup>C‐Labeled Novel Phosphodiesterase‐4 (PDE‐4) Inhibitor Jonathan Z. Ho, Charles S. Elmore, Michael A. Wallace, Helvetica Chimica Acta Medicinal ChemistryBioorganic ChemistryScheme 1BiochemistryNatural Sciences	2005	23

Page 1